Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: a randomized, double-blind, placebo-controlled, phase 1 clinical trial

Full metadata record
DC FieldValueLanguage
dc.contributorCentro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor(HVB) Hospital Vital Brazilpt_BR
dc.contributorCentro Bioindustrialpt_BR
dc.contributor.authorVanni, Taziopt_BR
dc.contributor.authorThomé, Beatrizpt_BR
dc.contributor.authorSparrow, Erinpt_BR
dc.contributor.authorMondini, Gabrielapt_BR
dc.contributor.authorSilveira, Daniela Haydee Ramospt_BR
dc.contributor.authorViscondi, Juliana Yukari Koidarapt_BR
dc.contributor.authorBraga, Patrícia Emíliapt_BR
dc.contributor.authorSilva, Anderson dapt_BR
dc.contributor.authorSalomão, Maria da Graçapt_BR
dc.contributor.authorPiorelli, Roberta de Oliveirapt_BR
dc.contributor.authorSantos, Joane do Pradopt_BR
dc.contributor.authorGattás, Vera Lúciapt_BR
dc.contributor.authorLucchesi, Maria Beatriz Bastospt_BR
dc.contributor.authorOliveira, Mayra Martho Moura dept_BR
dc.contributor.authorKoike, Marcelo Eijipt_BR
dc.contributor.authorAdami, Eduardo Alfredopt_BR
dc.contributor.authorAkamatsu, Milena Apetitopt_BR
dc.contributor.authorHo, Paulo Leept_BR
dc.contributor.authorPrecioso, Alexander Robertopt_BR
dc.date.accessioned2022-10-21T12:37:40Z-
dc.date.available2022-10-21T12:37:40Z-
dc.date.issued2022pt_BR
dc.identifier.citationVanni T, Thomé B, Sparrow E, Mondini G, Silveira DHR, Viscondi JYK, et al. Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: a randomized, double-blind, placebo-controlled, phase 1 clinical trial. PloS One. . doi:10.1371/journal.pone.0274943.pt_BR
dc.identifier.urihttps://repositorio.butantan.gov.br/handle/butantan/4565-
dc.description.abstractThe emergence of potentially pandemic viruses has resulted in preparedness efforts to develop candidate vaccines and adjuvant formulations. We evaluated the dose-sparing effect and safety of two distinct squalene-based oil-in-water adjuvant emulsion formulations (IB160 and SE) with influenza A/H7N9 antigen. This phase I, randomized, double-blind, placebo-controlled, dose-finding trial (NCT03330899), enrolled 432 healthy volunteers aged 18 to 59. Participants were randomly allocated to 8 groups: 1A) IB160 + 15μg H7N9, 1B) IB160 + 7.5μg H7N9, 1C) IB160 + 3.75μg H7N9, 2A) SE + 15μg H7N9, 2B) SE + 7.5μg H7N9, 2C) SE + 3.75μg H7N9, 3) unadjuvanted vaccine 15μg H7N9 and 4) placebo. Immunogenicity was evaluated through haemagglutination inhibition (HI) and microneutralization (MN) tests. Safety was evaluated by monitoring local and systemic, solicited and unsolicited adverse events (AE) and reactions (AR) 7 and 28 days after each study injection, respectively, whereas serious adverse events (SAE) were monitored up to 194 days post-second dose. A greater increase in antibody geometric mean titers (GMT) was observed in groups receiving adjuvanted vaccines. Vaccinees receiving IB160-adjuvanted formulations showed the greatest response in group 1B, which induced an HI GMT increase of 4.7 times, HI titers ≥40 in 45.2% of participants (MN titers ≥40 in 80.8%). Vaccinees receiving SE-adjuvanted vaccines showed the greatest response in group 2A, with an HI GMT increase of 2.5 times, HI titers ≥40 in 22.9% of participants (MN titers ≥40 in 65.7%). Frequencies of AE and AR were similar among groups. Pain at the administration site and headache were the most frequent local and systemic solicited ARs. The vaccine candidates were safe and the adjuvanted formulations have a potential dose-sparing effect on immunogenicity against influenza A/H7N9. The magnitude of this effect could be further explored.pt_BR
dc.description.sponsorship(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulopt_BR
dc.description.sponsorship(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.format.extente0274943pt_BR
dc.language.isoEnglishpt_BR
dc.relation.ispartofPloS Onept_BR
dc.rightsOpen accesspt_BR
dc.rights.urihttps://creativecommons.org/publicdomain/zero/1.0/pt_BR
dc.titleDose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: a randomized, double-blind, placebo-controlled, phase 1 clinical trialpt_BR
dc.typeArticlept_BR
dc.rights.licenseCC0pt_BR
dc.identifier.doi10.1371/journal.pone.0274943pt_BR
dc.contributor.external(WHO-SW) World Health Organization Switzerlandpt_BR
dc.contributor.externalInfectious Disease Research Institutept_BR
dc.contributor.external(BARDA) Biomedical Advanced Research and Development Authoritypt_BR
dc.contributor.external(USP) Universidade de São Paulopt_BR
dc.contributor.external(FIOCRUZ) Fundação Oswaldo Cruzpt_BR
dc.contributor.external(IAL) Instituto Adolfo Lutzpt_BR
dc.identifier.citationvolume17pt_BR
dc.identifier.citationissue10pt_BR
dc.relation.ispartofabbreviatedPloS Onept_BR
dc.contributor.butantanVanni, Tazio|:Desvinculado|:Centro de Ensaios Clínicos e Farmacovigilância|:PrimeiroAutorpt_BR
dc.contributor.butantanThomé, Beatriz|:Técnico|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanMondini, Gabriela|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanSilveira, Daniela Haydee Ramos|:Outros|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanViscondi, Juliana Yukari Koidara|:Outros|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanBraga, Patrícia Emília|:Outros|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanSilva, Anderson da|:Outros|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanSalomão, Maria da Graça|:Pesquisador|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanPiorelli, Roberta de Oliveira|:Outros|:(HVB) Hospital Vital Brazilpt_BR
dc.contributor.butantanSantos, Joane do Prado|:Outros|:Centro Bioindustrialpt_BR
dc.contributor.butantanGattás, Vera Lúcia|:Pesquisador|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanLucchesi, Maria Beatriz Bastos|:Outros|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanOliveira, Mayra Martho Moura de|:Outros|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanKoike, Marcelo Eiji|:Especialista|:Centro de Ensaios Clínicos e Farmacovigilânciapt_BR
dc.contributor.butantanAdami, Eduardo Alfredo|:Outros|:Centro Bioindustrialpt_BR
dc.contributor.butantanAkamatsu, Milena Apetito|:Outros|:Centro Bioindustrialpt_BR
dc.contributor.butantanHo, Paulo Lee|:Pesquisador|:Centro Bioindustrialpt_BR
dc.contributor.butantanPrecioso, Alexander Roberto|:Pesquisador|:Centro de Ensaios Clínicos e Farmacovigilância|:Autor de correspondênciapt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2020/07040-1pt_BR
dc.sponsorship.butantan(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦305430/2019-0pt_BR
dc.identifier.bvsccBR78.1pt_BR
dc.identifier.bvsdbIBProdpt_BR
dc.description.dbindexedYespt_BR
item.languageiso639-1English-
item.grantfulltextopen-
item.fulltextCom Texto completo-
item.openairetypeArticle-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0003-0398-9814-
crisitem.author.orcid0000-0002-3941-3756-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0002-9398-9182-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0003-3442-2343-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0001-8066-6774-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0001-5032-4570-
crisitem.author.orcid0000-0002-7227-185X-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0002-8193-3448-
crisitem.author.orcid0000-0003-3652-241X-
crisitem.author.orcid0000-0001-8657-9292-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journalissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journaleissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
Appears in Collections:Artigos


Files in This Item:

journal.pone.0274943.pdf
Description:
Size: 2.88 MB
Format: Adobe PDF
View/Open
Show simple item record

This item is licensed under a Creative Commons License Creative Commons